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Genetic testing for the two major breast cancer suscept-
ibility genes, BRCA1 and BRCA2 is widely available in
North America and Europe. A few other highly-penetrant
breast cancer genes have been found, including p53,
BRIP1 and PALB2, but families with mutations in these
are exceedingly rare. Arguably, the most relevant of the
post-BRCA genes, from a clinical point of view, is CHEK2,
which was first linked to breast cancer susceptibility in
2002.
In Poland, there are four founder mutations of CHEK2.
Three of these (IVS2+1G>A, del5395 and 1100delC) are
protein-truncating mutations and one (I157T) is a mis-
sense variant. We estimated the lifetime risk of breast
cancer for carriers of CHEK2 truncating mutations to be
20% for a woman with no affected relative, 28% for a
woman with one second-degree-relative affected, 34% for
a woman with one first-degree relative affected, and 44%
for a woman with both first- and one-second degree rela-
tive affected in the Polish population. In addition we esti-
mated that the lifetime risk for breast cancer for women
who carried two different CHEK2 mutations (a truncat-
ing mutation and the missense mutation) to be 42%.
Our results confirm that CHEK2 mutation screening
detects a clinically meaningful risk of breast cancer, and
women with a truncating mutation in CHEK2 and a
positive family history of breast cancer, and women who
carry two different CHEK2 mutations (the missense
mutation I157T and a truncating mutation) face a life-
time risk of breast cancer above 25% and are candidates
for MRI screening and for tamoxifen chemoprevention.
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